Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Aliment Pharmacol Ther 2010;32:1000–1006 Summary: Background Abnormal intestinal clearance is involved in the pathogenesis of small intestinal bacterial overgrowth (SIBO). It is known that partially hydrolysed guar gum affects intestinal motility. Eradication therapy of SIBO is based on antibiotic treatment: no data are available on the role of fibre supplementation in eradicating SIBO. Aim To assess whether the combination of partially hydrolysed guar gum and rifaximin is more effective than rifaximin alone in the treatment of SIBO. Methods A 50 g‐glucose breath test was given to 500 consecutive patients. Patients with a positive glucose breath test and predisposing conditions to SIBO entered into the study, and were randomized to receive rifaximin 1200 mg/day or rifaximin 1200 mg/day plus partially hydrolysed guar gum 5 g/day for 10 days. Patients completed a symptom questionnaire and glucose breath test both in basal condition and 1 month after withdrawal of therapy. Results Seventy‐seven patients had SIBO. Eradication rate of SIBO was 62.1% in the rifaximin group (both on per‐protocol and intention‐to‐treat analyses), and 87.1% (per‐protocol,P = 0.017) and 85.0% (intention‐to‐treat,P = 0.036) in the rifaximin‐plus‐partially hydrolysed guar gum group. Clinical improvement was observed in 86.9% and 91.1% of eradicated cases in rifaximin and rifaximin‐plus‐partially hydrolysed guar gum groups respectively (P = 0.677). Conclusion The combination of rifaximin with partially hydrolysed guar gum seems to be more useful in eradicating SIBO compared with rifaximin alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lupp, C., Robertson, M. L., Wickham, M. E., Sekirov, I., Champion, O. L., Gaynor, E. C., & Finlay, B. B. (2007) · Cell Host & Microbe · doi:10.1016/j.chom.2007.08.002 · Cited by 501
Small intestinal bacterial overgrowth in patients with irritable bowel syndrome
Posserud, I., Stotzer, P.-O., Björnsson, E. S., Abrahamsson, H., & Simrén, M. (2007) · Gut · doi:10.1136/gut.2006.108712 · Cited by 499 · cited 1×
“widely from 10% to 80% [8-13].”
Small Intestinal Bacterial Overgrowth: A Framework for Understanding Irritable Bowel Syndrome
Lin, H. C. (2004) · JAMA · doi:10.1001/jama.292.7.852 · Cited by 396 · cited 1×
“widely from 10% to 80% [8-13].”
Ford, A. C., Spiegel, B. M. R., Talley, N. J., & Moayyedi, P. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.06.031 · Cited by 351
Increased Incidence of Small Intestinal Bacterial Overgrowth During Proton Pump Inhibitor Therapy
Lombardo, L., Foti, M., Ruggia, O., & Chiecchio, A. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.12.022 · Cited by 350
Bouhnik, Y., Alain, S., Attar, A., Flourié, B., Raskine, L., Sanson-Le Pors, M. J., & Rambaud, J.-C. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01016.x · Cited by 199 · cited 2×
“intestine[1-4].”
BackgroundAssociation between hypothyroidism and small intestinal bacterial overgrowth
Lauritano, E. C., Bilotta, A. L., Gabrielli, M., Scarpellini, E., Lupascu, A., Laginestra, A., Novi, M., Sottili, S., Serricchio, M., Cammarota, G., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0606 · Cited by 140
Grover, M., Kanazawa, M., Palsson, O. S., Chitkara, D. K., Gangarosa, L. M., Drossman, D. A., & Whitehead, W. E. (2008) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2008.01142.x · Cited by 111
Peralta, S., Cottone, C., Doveri, T., Almasio, P. L., & Craxi, A. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.2628 · Cited by 88 · cited 1×
“14 However, hydrogen breath tests are commonly used in clinical practice, being more acceptable to patients and giving quicker information to the clinician.(15) Among them, glucose breath test (GBT) has proved to have the highest accuracy in diagnosing SIBO.”
BackgroundEffect of partially hydrolyzed guar gum on fecal output in human volunteers
Takahashi, H., Yang, S. L., Hayashi, C., Kim, M., Yamanaka, J., & Yamamoto, T. (1993) · Nutrition Research · doi:10.1016/s0271-5317(05)80557-3 · Cited by 57 · cited 1×
“proved[33-35].”
Cited by
Small intestinal bacterial overgrowth in Parkinson's disease
Tan, A. H., Mahadeva, S., Thalha, A. M., Gibson, P. R., Kiew, C. K., Yeat, C. M., Ng, S. W., Ang, S. P., Chow, S. K., Tan, C. T., et al. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.02.019 · Cited by 274
Gatta, L., & Scarpignato, C. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13928 · Cited by 266
Prevalence of small intestinal bacterial overgrowth in Chinese patients with Parkinson's disease
Niu, X.-L., Liu, L., Song, Z.-X., Li, Q., Wang, Z.-H., Zhang, J.-L., & Li, H.-H. (2016) · Journal of Neural Transmission · doi:10.1007/s00702-016-1612-8 · Cited by 64
“Importantly, breath tests for SIBO have not been standardized, and protocols differ with respect to the substrate used, sampling intervals, and test interpretation (Furnari et al. 2010).”
Background(2013) · PubMed · Cited by 15
Metadata
- Authors
- Furnari, M., Parodi, A., Gemignani, L., Giannini, E. G., Marenco, S., Savarino, E., Assandri, L., Fazio, V., Bonfanti, D., Inferrera, S., & Savarino, V.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2010-08-18
- Volume
- 32
- Issue
- 8
- Pages
- 1000-1006
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W1490740584
- Cited by
- 86
- References
- 10
- FWCI
- 2.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. https://app.cochat.ai/papers/10.1111/j.1365-2036.2010.04436.x
- The paper
- Furnari, M., Parodi, A., Gemignani, L., Giannini, E. G., Marenco, S., Savarino, E., Assandri, L., Fazio, V., Bonfanti, D., Inferrera, S., & Savarino, V. (2010). Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2010.04436.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.